The identification of oncogenic BRAF signaling increased interest in targeted inhibitors toward mutant BRAF variants, and the FDA has approved two targeted BRAF inhibitors, vemurafenib in 2011 and dabrafenib in 2013, for treatment of non-resectable BRAF V600E/K mutant melanoma. This evidence concerns the gene BRAF and melanoma.